Monday, June 13, 2011
Vertex Pharmaceuticals Inc., of Cambridge, Mass., reported final results from its pivotal Phase III STRIVE study showing that cystic fibrosis (CF) patients treated with VX-770 showed rapid improvements in lung function that were sustained through 48 weeks compared to placebo. Results showed a mean absolute improvement in lung function of 10.6 percent through week 24 and 10.5 percent through week 48.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.